These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8082409)

  • 1. Pharmacokinetic profile of methotrexate and 5-fluorouracil in normal and bilharzial-infested mice.
    Osman AM; Saad SF; Saad SY; el-Aaser AB; el-Merzabani MM
    Chemotherapy; 1994; 40(4):227-31. PubMed ID: 8082409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.
    el-Raghy I; Back DJ; Osman F; Nafeh MA; Orme ML
    Br J Clin Pharmacol; 1985 Oct; 20(4):313-6. PubMed ID: 4074599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of some anti-cancer drugs and combined chemotherapy on the pharmacokinetics of antipyrine in the rat.
    Skretkowicz J
    Pol J Pharmacol; 1995; 47(6):519-24. PubMed ID: 8868374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine.
    Homeida M; Salih SY; Branch RA
    Gut; 1978 Sep; 19(9):808-11. PubMed ID: 710970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered drug metabolism in hepatosplenic schistosomiasis.
    Brant PC; Prata A
    Rev Inst Med Trop Sao Paulo; 1979; 21(5):254-9. PubMed ID: 549210
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcium and phosphorus metabolic changes in children with hepatic bilharziasis.
    Hafez M; Mohareb SW; Hafez TA; Fahmi HA; Kassem AS; El Nahhas MR; El-Nady A
    Gaz Egypt Paediatr Assoc; 1975; 23(3-4):243-52. PubMed ID: 1230349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.
    de Bruijn EA; Driessen O; Leeflang P; van Strijen E; van den Bosch N; Hermans J
    Cancer Treat Rep; 1987 Dec; 71(12):1267-9. PubMed ID: 3690535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile composition in bilharzial hepatic fibrosis.
    el Masri SH; Lewin MR; Gumaa K
    Br J Surg; 1977 Jul; 64(7):487-9. PubMed ID: 922308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo.
    Vlaming ML; Pala Z; van Esch A; Wagenaar E; de Waart DR; van de Wetering K; van der Kruijssen CM; Oude Elferink RP; van Tellingen O; Schinkel AH
    Clin Cancer Res; 2009 May; 15(9):3084-93. PubMed ID: 19383815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
    Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
    J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy.
    Presant CA; Wolf W; Waluch V; Wiseman CL; Weitz I; Shani J
    J Clin Oncol; 2000 Jan; 18(2):255-61. PubMed ID: 10637237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.
    Yuan SH; Ge WH; Huo J; Wang XH
    Fundam Clin Pharmacol; 2009 Apr; 23(2):189-96. PubMed ID: 19298236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
    Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
    Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biliary and pancreatic excretion of methotrexate (MTX) and 5-FU on the MTX/5-FU sequential therapy].
    Suda Y; Akazawa S
    Gan To Kagaku Ryoho; 1990 Jul; 17(7):1357-63. PubMed ID: 2369139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid metabolism in bilharzial cirrhosis.
    Ghanem MH; Fahmy MH; Aboul-Kheir F; Mikhail MN; Guirgis FK
    Atherosclerosis; 1970; 12(1):55-61. PubMed ID: 5482261
    [No Abstract]   [Full Text] [Related]  

  • 17. Antipyrine pharmacokinetics in the pregnant rat.
    Dean M; O'Donnell L; Penglis S; Stock B
    Drug Metab Dispos; 1980; 8(4):265-7. PubMed ID: 6105062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance.
    Port RE; Daniel B; Ding RW; Herrmann R
    Oncology; 1991; 48(4):277-81. PubMed ID: 1891168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmaco-dynamic study of methotrexate (MTX) during intraperitoneal MTX/5-FU sequential therapy after gastric surgery].
    Nagahama T; Maruyama M; Irie T; Yoshida T; Kure N; Ebuchi M
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1786-9. PubMed ID: 10560395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.